Showing 30 results
Archival DescriptionObserved DALYs avoided and QALYs gained in ambulatory definite relapsing onset multiple sclerosis cohort exposed to first-generation disease-modifying therapies
Observed DALYs avoided and QALYs gained in ambulatory definite relapsing onset multiple sclerosis cohort exposed to first-generation disease-modifying therapies
First-generation disease-modifying therapy exposure effects on disability burden in ambulatory relapsing-onset MS : fixed effects regression model estimates from 1979-2010 Nova Scotia data
First-generation disease-modifying therapy exposure effects on disability burden in ambulatory relapsing-onset MS : fixed effects regression model estimates from 1979-2010 Nova Scotia data
Information sinkholes on the road to representative estimates of MS disability progression speed ....
Information sinkholes on the road to representative estimates of MS disability progression speed ....
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Estimates of MS disability progression natural history speed before and after applying censoring bias reduction methods to observational Nova Scotia EDSS-clinic-visit 1979-2010 data
Modelling health outcomes in relapsing-remitting-onset multiple sclerosis cohorts treated with disease-modifying drugs that delay disability progression
Modelling health outcomes in relapsing-remitting-onset multiple sclerosis cohorts treated with disease-modifying drugs that delay disability progression
Multiple sclerosis disease-modifying drug and health care costs in Nova Scotia, 1989 -2003 / Vern Hicks, Murray G. Brown, I.S. Sketris
Multiple sclerosis disease-modifying drug and health care costs in Nova Scotia, 1989 -2003 / Vern Hicks, Murray G. Brown, I.S. Sketris
How effective are new drugs in delaying disability progression in relapsing remitting onset multiple sclerosis? A subgroup analysis
How effective are new drugs in delaying disability progression in relapsing remitting onset multiple sclerosis? A subgroup analysis
National Multiple Sclerosis Society (NMSS) COSTRIMS study
National Multiple Sclerosis Society (NMSS) COSTRIMS study
EDSS natural history atlas : multiple sclerosis disability progression in Nova Scotia, 1979-2004
EDSS natural history atlas : multiple sclerosis disability progression in Nova Scotia, 1979-2004
Clinical effectiveness of disease modifying treatment (DMT) that delays disability progression in relapsing/remitting-onset MS
Clinical effectiveness of disease modifying treatment (DMT) that delays disability progression in relapsing/remitting-onset MS
Cost-effectiveness of multiple sclerosis drugs in the "real world"
Cost-effectiveness of multiple sclerosis drugs in the "real world"
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world" : final report
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world" : final report
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world"
Effectiveness and cost-effectiveness of new drugs on multiple sclerosis disability progression in the "real world"
Effectiveness and cost-effectiveness of new multiple sclerosis drugs the "real world" : final report to Health Policy Research Program, Health Canada
Effectiveness and cost-effectiveness of new multiple sclerosis drugs the "real world" : final report to Health Policy Research Program, Health Canada
MS cost-effectiveness study correspondence and meeting notes
MS cost-effectiveness study correspondence and meeting notes
Dalhousie MS Research Group meeting minutes
Dalhousie MS Research Group meeting minutes
Multiple sclerosis net benefits feasibility study
Multiple sclerosis net benefits feasibility study
Letter of intent to Health Canada on Assessing the Effectiveness of Marketed Pharmaceutical Products in the "Real World"
Letter of intent to Health Canada on Assessing the Effectiveness of Marketed Pharmaceutical Products in the "Real World"
Multiple Sclerosis PharmacoEconomic Evaluation Tool (MS PEET) version 2 users manual
Multiple Sclerosis PharmacoEconomic Evaluation Tool (MS PEET) version 2 users manual
Evaluation of health-related quality of life utility measures in patients with multiple sclerosis
Evaluation of health-related quality of life utility measures in patients with multiple sclerosis
Abstract, poster, and presentations on MS research
Abstract, poster, and presentations on MS research
Treatment start and treatment duration as determinants of treatment program health outcomes and cost-effectiveness
Treatment start and treatment duration as determinants of treatment program health outcomes and cost-effectiveness
Cost-effectiveness of Interferon Beta-1B in slowing multiple sclerosis disability progression : first estimates
Cost-effectiveness of Interferon Beta-1B in slowing multiple sclerosis disability progression : first estimates
A therapeutic and economic assessment of Betaseron in multiple sclerosis
A therapeutic and economic assessment of Betaseron in multiple sclerosis
Modelling disease progression & treatment effects in multiple sclerosis within a cost-effectiveness study / Murray G. Brown & Chris Skedgel
Modelling disease progression & treatment effects in multiple sclerosis within a cost-effectiveness study / Murray G. Brown & Chris Skedgel
Measuring the consequences of MS in Canada : economic effects
Measuring the consequences of MS in Canada : economic effects
Serono Canada grant application and report
Serono Canada grant application and report
Serono grant application for Multiple Sclerosis Health Care Costs in Nova Scotia: A Population-based Life-cycle Study
Serono grant application for Multiple Sclerosis Health Care Costs in Nova Scotia: A Population-based Life-cycle Study
Murray G. Brown fonds
Murray G. Brown fonds